Skip to content

Impact of Vitamin C on the Reduction of Bleeding Risk after Percutaneous Renal Biopsy: A Multi-center Randomized Controlled Trail

Impact of Vitamin C on the Reduction of Bleeding Risk after Percutaneous Renal Biopsy: A Multi-center Randomized Controlled Trail

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300079026
Enrollment
Unknown
Registered
2023-12-24
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

percutaneous ultrasound-guided renal biopsy

Interventions

intervention group:100 mL normal saline plus 500 mg vitamin C for 2 d(1 d before and after the biopsy), with intravenous administration
control group:100 mL normal saline for 2 d(1 d before and after the biopsy), with intravenous administration

Sponsors

Xijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.receiving written Informed Consent Form; 2.ranging from 18 years of age to 80; 3. accepting percutaneous ultrasound-guided renal biopsy; 4.blood pressure was lower than 140/90 mmHg with or without anti-hypertension therapy; 5.estimated glomerular filtration rate(eGFR) was equal or higher than 60 ml/min/1.73m²; 6.with normal coagulation function(PT>7.7s,INR>0.91s,APTT>26.6s,TT>14.5s,FIB>1.93s); 7.Plt>100*10^9/L ,Hb of males>70g/L(females>60g/L).

Exclusion criteria

Exclusion criteria: 1.patients with predisposition to allergies or history of adverse reaction from Vitamin C injection; 2.solitary kidney; 3.kidney cancer; 4.pregnant women; 5.patients with oliguria (urine volume<400ml/24h); 6.patients with diseases which could influence coagulation function such as thalassemia ,and cystinuria ,and glucose-6-phosphate dehydrogenase deficiency ,and etc. 7.Medications with nonsteroidal anti-inflammatory drugs(NSAIDs),antiplatelet agents or heparins were withdrawn before kidney biopsy ,eliminating interferences in hemostasis.

Design outcomes

Primary

MeasureTime frame
severe bleeding events;size of hematoma;

Secondary

MeasureTime frame
adverse drug reaction;other complications;Vital signs;physical examination;laboratory examination;ultrasonic examinations;

Countries

China

Contacts

Public ContactHe, Lijie

Department of Nephrology, Xijing Hospital, The Fourth Military Medical University

43218204@qq.com+86 150 9118 5737

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026